Brind.

UniQure partnered with the FDA regarding AMT-130, an experimental gene therapy for Huntington's disease, while ClearPoint provided infusion disposables.

1 report, 0 independent Updated Jun 23

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

SpeculativeNo independent reporting found

Who's involved

What this event is mainly about

UniQure (Netherlands)FDA

Keep exploring

The entities involved

UniQure (Netherlands)
company in Amsterdam, Netherlands
- Trump pledged to unleash American oil and gas and advised investors on market timing in August 2025.Sun 04:14
FDA
- Generic medicine services are seeking approval for launch from the FDA.Mon 17:49
- A company is seeking FDA feedback on its NEO212 program, with a meeting scheduled at the FDA's White Oak campus.Mon 14:56

Coverage

Newest first; wire copies grouped

Jun 23Unknown outlet